AJTMH Tropical Medicine and Hygiene News
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am. J. Trop. Med. Hyg., 43(2), 1990, pp. 159-166
Copyright © 1990 by The American Society of Tropical Medicine and Hygiene

This Article
Right arrow Full Text (PDF)
Right arrow A correction has been published
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gallerano, R. H.
Right arrow Articles by Sosa, R. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gallerano, R. H.
Right arrow Articles by Sosa, R. R.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*ALLOPURINOL
Medline Plus Health Information
*Chagas Disease

Therapeutic Efficacy of Allopurinol in Patients with Chronic Chagas' Disease

Rafael H. Gallerano, J. Joseph Marr AND Raul R. Sosa
Medical School of the National University of Cordoba, First Service of Clinical Medicine, Cordoba Hospital Student Health Service, National University of Cordoba, Cordoba, Argentina, University of Colorado Health Sciences Center, Denver, Colorado

Laboratory and animal studies have demonstrated that pyrazolopyrimidines have significant activity against Trypanosoma cruzi. This clinical investigation was to ascertain the efficacy of allopurinol in the treatment of chronic Chagas' disease. Of 307 patients studied, 91 were untreated; the remaining 216 were divided into 4 treatment groups. These corresponded to 600 or 900 mg/day of allopurinol for 60 days and benznidazole or nifurtimox at conventional dosage regimens. Patients were evaluated clinically, serologically, and parasitologically. Allopurinol was found to be as efficacious as the conventional therapeutic modalities in eliminating the parasitemia and rendering patients seronegative. Adverse reactions occurred in 11% of patients who received allopurinol and in 30% of those receiving nitrofurans. Reactions with the conventional therapy were more frequent and of a more serious nature. Oral allopurinol is as effective as the nitrofurans, but has none of the side effects.




This article has been cited by other articles:


Home page
 Am J Trop Med HygHome page
A. RASSI, A. O. LUQUETTI, A. RASSI JR, G. G. RASSI, S. G. RASSI, I. G. DA SILVA, and A. G. RASSI
SPECIFIC TREATMENT FOR TRYPANOSOMA CRUZI: LACK OF EFFICACY OF ALLOPURINOL IN THE HUMAN CHRONIC PHASE OF CHAGAS DISEASE
Am J Trop Med Hyg, January 1, 2007; 76(1): 58 - 61.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
X. Coronado, I. Zulantay, M. Rozas, W. Apt, G. Sanchez, J. Rodriguez, S. Ortiz, and A. Solari
Dissimilar distribution of Trypanosoma cruzi clones in humans after chemotherapy with allopurinol and itraconazole
J. Antimicrob. Chemother., July 1, 2006; 58(1): 216 - 219.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
K. Chaudhary, J. A. Darling, L. M. Fohl, W. J. Sullivan Jr., R. G. K. Donald, E. R. Pfefferkorn, B. Ullman, and D. S. Roos
Purine Salvage Pathways in the Apicomplexan Parasite Toxoplasma gondii
J. Biol. Chem., July 23, 2004; 279(30): 31221 - 31227.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1990 by the American Society of Tropical Medicine and Hygiene.